Ophthalmology Biosimilars Market Report 2028

Ophthalmology Biosimilars Market Report 2028


Pune, India, Sept. 07, 2021 (News) — The global ophthalmology biosimilars market size is expected to gain momentum owing to the increasing prevalence of ophthalmological disorders during the forecast period. This information is published by Fortune Business Insights™ in an upcoming report, titled, “Ophthalmology Biosimilars Market, 2021-2028.” The key variables influencing the market positively include an increase in the prevalence of ocular illness, an increase in the recurrence of retinal disease, an increase in the elderly population, and an increase in diabetes cases. The increasing number of upcoming products by such major corporations indicates the overall growth of the industry in the near future. For instance, in July 2019, Allergan and Amgen Inc. released a new version of a novel medicine for usage and commercialization in the United States. The firm launched ‘Kanjinti,’ a trastuzumab biosimilar for usage in the United States.

Significant Industry Developments of the Ophthalmology Biosimilars Market Include:

July 2019: Regeneron’s newer versions and pipeline are likely to outperform the competition for the eylea biosimilar, which will be a collaboration initiative between Sanofi and Bayer AG.

Request a Sample Copy of the Research Report:


Increasing Frequency of Eye-Related Disease to Stimulate Growth

The global ophthalmology biosimilars market growth is expected to grow due to the increasing eye-disease cases during the projected period. The increasing prevalence of eye-related clutters like as diabetic retinopathy, macular degeneration, and presbyopia is expected to drive display development. One of the key factors driving the market is the availability of strong pipeline products and the growing sales volume of ophthalmic medicines for retinal diseases.

Additionally, rising COVID-19-related eye diseases are expected to drive market growth. According to research published in the Indian Journal of Ophthalmology, 31.6 percent of COVID-19 cases in China showed ocular involvement, while 91.7 percent of COVID-19 cases tested positive for associated infections.

Click here to get the short-term and long-term impact of COVID-19 on this market.

Please visit: https://www.fortunebusinessinsights.com/ophthalmology-biosimilars-market-103109

Increasing R&D Activities to Promote Growth in Asia Pacific

Asia Pacific is expected to hold the largest global ophthalmology biosimilars market share during the forecast period. With the higher incidence of ocular diseases, increasing consumer awareness and local businesses are launching strategic operations to create and market new therapeutic alternatives for patients.

North America is expected to have a sizable share of the market. The availability of a strong level of consumer awareness and a good healthcare network, and the presence of prominent companies in this region is expected to boost the growth in the region.

Have Any Query? Ask Our Experts:


What does the Report Offer?

The report provides a descriptive overview of the ophthalmology biosimilars industry, outlining their uses, benefits, and limits, among other things. By understanding the trends defining and driving the market, the report gives you an advantage when building business plans.

List of Manufacturers in the Ophthalmology Biosimilars Market include:

  • Zydus Cadila
  • Biocon
  • Formycon AG
  • Xbrane Biopharma
  • Pfenex
  • Coherus BioSciences
  • Biocad
  • Allergen
  • mAbxience
  • Intas Pharmaceuticals

Get your Customized Research Report:



  • Details such as revenues, market share, strategies, growth rate, product & their pricing by region/country for all major companies
  • Details in relation to prevalence, incidence, patient numbers, distribution of patients, average price of treatment, etc.
  • Number of end user facilities by region/country and average annual spending or procurement of devices by type of end user facility
  • Number of procedures and average price of procedures
  • Replacement rate and pricing of capital equipment
  • Market dynamics in relation to the market under focus – Drivers, restraints, trends, and opportunities
  • Market & technological trends, new product developments, product pipeline.

About Us:

Fortune Business Insights™ offers expert corporate analysis and accurate data, helping organizations of all sizes make timely decisions. We tailor innovative solutions for our clients, assisting them to address challenges distinct to their businesses. Our goal is to empower our clients with holistic market intelligence, giving a granular overview of the market they are operating in.

Our reports contain a unique mix of tangible insights and qualitative analysis to help companies achieve sustainable growth. Our team of experienced analysts and consultants use industry-leading research tools and techniques to compile comprehensive market studies, interspersed with relevant data.

At Fortune Business Insights™ we aim at highlighting the most lucrative growth opportunities for our clients. We, therefore, offer recommendations, making it easier for them to navigate through technological and market-related changes. Our consulting services are designed to help organizations identify hidden opportunities and understand prevailing competitive challenges.

Contact Us:

Fortune Business Insights™ Pvt. Ltd.

308, Supreme Headquarters,

Survey No. 36, Baner,

Pune-Bangalore Highway,

Pune – 411045, Maharashtra, India.


US :+1 424 253 0390

UK : +44 2071 939123

APAC : +91 744 740 1245

Email: [email protected]

Fortune Business Insights™

LinkedIn | Twitter | Blogs

Health News Highlights

  • Headline: Ophthalmology Biosimilars Market Report 2028
  • Check all news and articles from the Heath news updates.
Disclaimer: If you need to update/edit this article then please visit our help center. For Latest Updates Follow us on Google News


Source link

Robert Swift

Leave a Reply

Your email address will not be published. Required fields are marked *